[
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Irrespective of the presence of a nanomaterial, the existing requirements for safety assessment according to EFSA guidances for conventional materials under relevant regulations must be followed (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "This SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure (see Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The present Guidance proposes a structured pathway for carrying out safety assessment of nanomaterials in food/feed and related applications (see Figure 2) and provides practical suggestions for the types of testing needed and the methods that can be used.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "How to use this Guidance in relation to sectoral EFSA guidances\nThe SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The SC Guidance on Nano‐RA is complementary to the EFSA sectoral guidances that will remain the frameworks of the risk assessment procedure as depicted in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The schematic general outline for risk assessment of nanomaterials is shown in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Materials to be Assessed under this Guidance\nFigure 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2)The first step in the risk assessment is to identify whether the material under consideration is a nanomaterial, has properties characteristic of the nanoscale or contains a fraction of nanoparticles.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Step 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano‐RA (detail from Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Physico‐chemical characterisation of nanomaterial\nFigure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nStep 1: Physico‐chemical characterisation (detail from Figure 2)The step preceding risk assessment is problem formulation and deciding whether the risk assessment includes applications of nanoscience and nanotechnology.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Step 1: Physico‐chemical characterisation (detail from Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Anticipated uses, use levels and potential oral exposure to the nanomaterial should be investigated as shown in Figure 5 and the paragraphs below.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Steps in oral exposure assessment (detail from Figure 2). (a) If it cannot be determined whether a nanomaterial is present in the food/feed matrix or food simulant it should be assumed that nanomaterial is present. (b) The assessment of degradation products that are still in the form of nanoparticles should continue as presented in this Guidance.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2)7.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This study should allow for the identification of nanomaterials with the potential to cause immunological, proliferative, neurotoxic, reproductive organ effects or endocrine‐mediated effects that may warrant further in‐depth investigation in Step 4.\n\n\n•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nSteps in testing (detail from Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "•A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.\n\n\n•In Step 2, the rate of degradation of the nanomaterial to a non‐nanomaterial form under conditions representative of the gastrointestinal tract should be investigated.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "A stepwise approach (Figure 6) should be adopted for hazard identification and hazard characterisation to avoid unnecessary testing of nanomaterials.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Steps in testing (detail from Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In vitro gastrointestinal digestion\nAssessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Assessment of the dissolution/degradation rate of nanomaterials in conditions representative of the human gastrointestinal tract is considered a key first step in the stepwise approach (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Furthermore, if it cannot be demonstrated that the material quickly degrades, one should continue to Step 2 (Figure 2 or 6).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, in vitro tests with the nanomaterial are to be performed in Step 2 (see Figure 6), particularly the lysosomal degradation test as described in Section 7.2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Risk characterisation of nanomaterial\nFigure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nRisk characterisation (detail from Figure 2)Conceptually, the risk characterisation of nanomaterials does not differ per se from that of a conventional material and needs to be integrated in the risk characterisation under the sectoral legislation.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Risk characterisation (detail from Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]